Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
10.9758/cpn.2019.17.2.155
- Author:
Jong Hyun JEONG
1
;
Won Myong BAHK
;
Young Sup WOO
;
Jung Goo LEE
;
Moon Doo KIM
;
InKi SOHN
;
Se Hoon SHIM
;
Duk In JON
;
Jeong Seok SEO
;
Won KIM
;
Hoo Rim SONG
;
Kyung Joon MIN
;
Bo Hyun YOON
Author Information
1. Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- Publication Type:Review
- Keywords:
Bipolar disorder;
Pharmacotherapy;
Algorithm;
Treatment guideline;
Korean Medication Algorithm Project for Bipolar Disorder 2018
- MeSH:
Aripiprazole;
Bipolar Disorder;
Depression;
Drug Therapy;
Lithium;
Paliperidone Palmitate;
Prescriptions;
Quetiapine Fumarate;
Risperidone;
Valproic Acid
- From:Clinical Psychopharmacology and Neuroscience
2019;17(2):155-169
- CountryRepublic of Korea
- Language:English
-
Abstract:
The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018) with other recently published guidelines for treating bipolar disorder. We reviewed a total of five recently published global treatment guidelines and compared treatment recommendation of the KMAP-BP 2018 with those of other guidelines. For initial treatment of mania, there were no significant differences across treatment guidelines. All guidelines recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or a combination of an MS with an AAP as a first-line treatment strategy for mania. However, the KMAP-BP 2018 did not prefer monotherapy with MS or AAP for psychotic mania. Quetiapine, olanzapine and aripiprazole were the first-line AAPs for nearly all phases of bipolar disorder across guidelines. Most guidelines advocated newer AAPs as first-line treatment options for all phases while lamotrigine was recommended for depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. As research evidence accumulated over time, recommendations of newer AAPs (such as asenapine, cariprazine, paliperidone, lurasidine, long-acting injectable risperidone and aripiprazole once monthly) became prominent. KMAP-BP 2018 guidelines were similar to other guidelines, reflecting current changes in prescription patterns for bipolar disorder based on accumulated research data. Strong preference for combination therapy was characteristic of KMAP-BP 2018, predominantly in the treatment of psychotic mania and severe depression. Further studies were needed to address several issues identified in our review.
